Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831505 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
A Phase 1 study, sponsored by Presage Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01831505 is a Phase 1 study that has completed, run by Presage Biosciences. The registered enrollment target is 4 participants.
The verdict
NCT01831505, a Phase 1 study, has completed, sponsored by Presage Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph nodes in situ respond to standard of care therapeutics precisely microinjected with the CIVO(tm) microdosing system.
Interventions
- DRUG Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01831505
The ClinicalTrials.gov registry entry for NCT01831505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presage Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them is the first listed.
NCT01831505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01831505 about?
NCT01831505 is a clinical study titled "Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents". Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurr...
What is the current status of trial NCT01831505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01831505?
The interventions under investigation include: Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them (DRUG).
Who is sponsoring clinical trial NCT01831505?
This trial is sponsored by Presage Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.